Watch out, Gilead: TG Therapeutics wins FDA nod for potentially safer Zydelig rivalrnings season continues to show COVID-19 uncertainty

The PI3K cancer drug family just got a new member, and it’s a potentially safer option than existing players, including Gilead Sciences’ Zydelig.

Friday, TG Therapeutics said it had won an accelerated FDA go-ahead for Ukoniq (umbralisib) for two types of blood cancer. It’s now allowed to treat relapsed or refractory marginal zone lymphoma (MZL) after at least one prior anti-CD20-based regimen and follicular lymphoma (FL) in patients who have failed at least three previous treatments.